Palvella Therapeutics PVLA Increase Decrease In Derivative Liabilities
Increase Decrease In Derivative Liabilities at other companies
Other financials
Where this comes from
Reported directly by Palvella Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:IncreaseDecreaseInDerivativeLiabilities.
The official record: Palvella Therapeutics’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →
Ask your AI about Palvella Therapeutics's increase decrease in derivative liabilities.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Palvella Therapeutics's increase decrease in derivative liabilities?
- Palvella Therapeutics (PVLA) reported increase decrease in derivative liabilities of $116K in Q1 2026.
- How has Palvella Therapeutics's increase decrease in derivative liabilities changed year-over-year?
- Palvella Therapeutics's increase decrease in derivative liabilities increased by 54.7% year-over-year, from $75K to $116K.
- What is the long-term trend for Palvella Therapeutics's increase decrease in derivative liabilities?
- Over 2 years (2023 to 2025), Palvella Therapeutics's increase decrease in derivative liabilities has grown at a -9.9% compound annual growth rate (CAGR), from -$485K to $394K.
- What does increase decrease in derivative liabilities mean?
- Captures the net change in the fair value of derivative financial instruments classified as liabilities on the balance sheet. Fluctuations in this metric often result from changes in market conditions, stock price volatility, or the passage of time affecting embedded derivatives. Monitoring this helps assess the impact of non-operating financial risks on the company's reported net income.